Obese Patients With Lynch Syndrome at Higher Risk for Colorectal Cancer

Share this content:
Obesity is associated with a significantly increased risk of colorectal cancer in patients with Lynch syndrome.
Obesity is associated with a significantly increased risk of colorectal cancer in patients with Lynch syndrome.

Obesity is associated with a significantly increased risk of colorectal cancer in patients with Lynch syndrome. However, regular aspirin use may lower that risk, according to a recent study published online ahead of print in the Journal of Clinical Oncology.

Researchers led by Mohammad Movahedi, MD, PhD, of the Beheshti University of Medical Sciences in Iran recruited 937 patients with Lynch syndrome to the CAPP2 study where they were randomly assigned to either aspirin (600 mg daily) or aspirin placebo, as well as resistant starch (30 g daily) or starch placebo.

They wanted to determine the link between increased adiposity and risk of colorectal cancer in patients with Lynch syndrome.

At a mean follow-up of 55.7 months, the researchers found that 55 of the patients developed colorectal cancer. Colorectal cancer risk was 2.41 times greater in obese participants when compared with the reference group of underweight and normal-weight participants. Risk of colorectal cancer was increased by 7% for each 1 kg/m2 increase in body mass index.

In addition, risk of all Lynch syndrome-related cancers in obese participants was 1.77 times greater than the reference group. Upon subgroup analysis, obesity was associated with a 3.72 times greater risk of colorectal cancer in those patients with MLH1 mutation, but no excess risk was found in MSH2 or MSH6 mutations.

RELATED: FIT-Based Screening Impacts Proximal, Distal Colorectal Cancer Rates

However, the obesity-related excess risk of colorectal cancer was found to be exclusive to patients who were assigned to the aspirin placebo group.

“Obesity is associated with substantially increased colorectal cancer risk in patients with Lynch syndrome, but this risk is abrogated in those taking aspirin,” the authors concluded.

Reference

  1. Movahedi M, Bishop DT, Macrae F, et al. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 study. J Clin Oncol.2015. [epub ahead of print]. doi: 10.1200/JCO.2014.58.9952.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters